In a type of liver cell called HepG2, a protein called HNF1α is the main switch that turns on the PCSK9 gene — when scientists turned off HNF1α, PCSK9 dropped by 85%, but turning off a similar protein, HNF1β, only cut it by 44%.
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
definitive
Can make definitive causal claims
Assessment Explanation
The claim is supported by three complementary experimental methods (supershift EMSA, ChIP, and siRNA knockdown) that together establish both binding specificity and functional consequence. The quantitative comparison (85% vs. 44%) is precise and derived from controlled knockdown experiments, making a definitive claim about predominance justified. The use of multiple orthogonal methods reduces confounding and strengthens causal inference within the in vitro system.
Context Details
Domain
medicine
Population
in_vitro
Subject
HNF1α and HNF1β transcription factors in HepG2 cells
Action
bind to and regulate the PCSK9 promoter, leading to reduced expression upon knockdown
Target
PCSK9 gene expression levels
Intervention Details
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Evidence from Studies
Supporting (1)
Hepatocyte Nuclear Factor 1α Plays a Critical Role in PCSK9 Gene Transcription and Regulation by the Natural Hypocholesterolemic Compound Berberine*
The study found that in liver cells, a protein called HNF1α is the main switch that turns on the PCSK9 gene, more than another similar protein called HNF1β — just like the claim says.